<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cardiovascular</journal-id><journal-title-group><journal-title xml:lang="ru">Кардиоваскулярная терапия и профилактика</journal-title><trans-title-group xml:lang="en"><trans-title>Cardiovascular Therapy and Prevention</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1728-8800</issn><issn pub-type="epub">2619-0125</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">cardiovascular-976</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРЫ ЛИТЕРАТУРЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEW ARTICLES</subject></subj-group></article-categories><title-group><article-title>Васкулярные ростовые факторы в патогенезе гипертензивных состояний</article-title><trans-title-group xml:lang="en"><trans-title>Vascular growth factors in hypertensive state pathogenesis</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гомазков</surname><given-names>О. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Gomazkov</surname><given-names>O. A.</given-names></name></name-alternatives><bio xml:lang="ru"/><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>НИИ биомедицинской химии им. В.Н. Ореховича РАМН, Москва</institution></aff><aff xml:lang="en"><institution>V.N. Orekhovich Research Institute of Biomedical Chemistry, Russian Academy of Medical Science, Moscow</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2005</year></pub-date><pub-date pub-type="epub"><day>20</day><month>06</month><year>2005</year></pub-date><volume>4</volume><issue>3, ч.I</issue><fpage>93</fpage><lpage>103</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Гомазков О.А., 2005</copyright-statement><copyright-year>2005</copyright-year><copyright-holder xml:lang="ru">Гомазков О.А.</copyright-holder><copyright-holder xml:lang="en">Gomazkov O.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://cardiovascular.elpub.ru/jour/article/view/976">https://cardiovascular.elpub.ru/jour/article/view/976</self-uri><abstract><p>Обобщение и анализ информации о роли нейротрофических и ростовых факторов в формировании сосудистой патологии, артериальной гипертонии (АГ) и органных поражений (ОП) позволяет определить новые позиции терапевтической стратегии. Становится все более очевидным, что помимо систем пептидных регуляторов (ангиотензин II, эндотелин-1, атриальные натрийуретические факторы), катехоламинов и др. в патогенезе кардиоваскулярных расстройств принимают участие полипептидные ростовые и нейротрофические факторы, встроенные в общую систему химической регуляции. Они выполняют функцию регуляторов нормальных и дисбалансированных процессов и непосредственно причастны к триаде «окислительные стресс – воспаление – эндотелиальная дисфункция», служащей основой развития АГ и ОП. Среди этих факторов первостепенный интерес представляют: Эндотелиальный фактор роста сосудов, Инсулиноподобные факторы роста, Тромбоцитарный ростовой фактор, Трансформирующие ростовые факторы, Фактор роста фибробластов, Фактор некроза опухоли. Структурные и функциональные особенности этих соединений и их значимость в качестве возможных посредников и/или предикторов и мишеней патологических процессов в сосудистой стенке представлены в настоящей статье.</p></abstract><trans-abstract xml:lang="en"><p>Summarizing and analyzing the information on the role of neurotrophic and growth factors in vascular pathology, arterial hypertension (AH), and organ damage (OD) pathogenesis, enables us to set new targets for treatment strategy. It is more and more evident that, besides the systems of peptide regulators (angiotensin II, endothelin-1, atrial natriuretic factors), catecholamines, etc., cardiovascular pathology pathogenesis is influenced by polypeptide growth and neurotrophic factors, participating in the complex chemical regulation process. They act as regulators of normal and pathological processes, and are directly linked with the triade “oxidative stress-inflammation-endothelial dysfunction”, that is crucial in AH and OD pathogenesis. Among these factors, the most prospective are: endothelial vascular growth factor, insulin-like growth factors, platelet growth factor, transforming growth factors, fibroblast growth factor, tumor necrosis factor. Structural and functional features of these substances, together with their role as possible mediators and/or predictors and targets in vascular pathology processes, are described in this article.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>ростовые и нейротрофические факторы</kwd><kwd>сосудистое воспаление</kwd><kwd>дисфункция эндотелия</kwd><kwd>артериальная гипертензия</kwd></kwd-group><kwd-group xml:lang="en"><kwd>growth and neurothrophic factors</kwd><kwd>vascular inflammation</kwd><kwd>endothelial dysfunction</kwd><kwd>arterial hypertension</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Ланкин В.З., Тихадзе А.К., Беленков Ю.Н. Свободнорадикальные процессы при заболеваниях сердечно-сосудистой системы. Кардиология 2000; 40(7): 48-61.</mixed-citation><mixed-citation xml:lang="en">Ланкин В.З., Тихадзе А.К., Беленков Ю.Н. Свободнорадикальные процессы при заболеваниях сердечно-сосудистой системы. Кардиология 2000; 40(7): 48-61.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Touyz RM. Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance? Hypertension 2004; 44(3): 248-52.</mixed-citation><mixed-citation xml:lang="en">Touyz RM. Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance? Hypertension 2004; 44(3): 248-52.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Гомазков О.А. Молекулярные и физиологические аспекты эндотелиальной функции. Роль эндогенных химических регуляторов. Успехи физиол наук 2000;31(4):48-62.</mixed-citation><mixed-citation xml:lang="en">Гомазков О.А. Молекулярные и физиологические аспекты эндотелиальной функции. Роль эндогенных химических регуляторов. Успехи физиол наук 2000;31(4):48-62.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Задионченко В.С., Адашева Т.В., Сандомирская А.П., Суворова С.С. Дисфункция эндотелия, артериальная гипертония: терапевтические возможности. Кардиоваскулярная терапия и профилактика 2002;1(2):79-90.</mixed-citation><mixed-citation xml:lang="en">Задионченко В.С., Адашева Т.В., Сандомирская А.П., Суворова С.С. Дисфункция эндотелия, артериальная гипертония: терапевтические возможности. Кардиоваскулярная терапия и профилактика 2002;1(2):79-90.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Небиеридзе Д.В., Оганов Р.Г. Дисфункция эндотелия как фактор риска атеросклероза, клиническое значение ее коррекции. Кардиоваск тер профил 2003; 2(4): 68-86.</mixed-citation><mixed-citation xml:lang="en">Небиеридзе Д.В., Оганов Р.Г. Дисфункция эндотелия как фактор риска атеросклероза, клиническое значение ее коррекции. Кардиоваск тер профил 2003; 2(4): 68-86.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Курбанов Р.Д., Елисеева М.Р., Турсунов Р.Р. и др. Гуморальные маркеры дисфункции эндотелия при эссенциальной гипертонии. Кардиология 2003; 43(7): 61-4.</mixed-citation><mixed-citation xml:lang="en">Курбанов Р.Д., Елисеева М.Р., Турсунов Р.Р. и др. Гуморальные маркеры дисфункции эндотелия при эссенциальной гипертонии. Кардиология 2003; 43(7): 61-4.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Suzuki Y, Ruiz-Ortega M, Lorenzo O,et al. Inflammation and angiotensin II. Int J Biochem Cell Biol 2003; 35(6): 881-900.</mixed-citation><mixed-citation xml:lang="en">Suzuki Y, Ruiz-Ortega M, Lorenzo O,et al. Inflammation and angiotensin II. Int J Biochem Cell Biol 2003; 35(6): 881-900.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">El Bekay R, Alvarez M, Monteseirin J, et al. Oxidative stress is critical mediator of the angiotensin II signal in human neutrophils: involvement of mitogen-activated protein kinase, calcineurin, and the transcription factor NF-kappaB. Blood 2003; 102(2): 662-71.</mixed-citation><mixed-citation xml:lang="en">El Bekay R, Alvarez M, Monteseirin J, et al. Oxidative stress is critical mediator of the angiotensin II signal in human neutrophils: involvement of mitogen-activated protein kinase, calcineurin, and the transcription factor NF-kappaB. Blood 2003; 102(2): 662-71.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Constanzo A, Moretti F, Burgio VL, et al. Endothelial activation of angiotensin II trougth NFkappaB and p38 pathways: Involvement of NFkappaB-inducible kinase, free oxygen radicals, and selective inhibition by aspirin. J Cell Physiol 2003; 195(3): 402-10.</mixed-citation><mixed-citation xml:lang="en">Constanzo A, Moretti F, Burgio VL, et al. Endothelial activation of angiotensin II trougth NFkappaB and p38 pathways: Involvement of NFkappaB-inducible kinase, free oxygen radicals, and selective inhibition by aspirin. J Cell Physiol 2003; 195(3): 402-10.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Cominacini L, Pasini A, Garbin U, et al. Zofenopril inhibits the expression of adhesion molecules on endothelial cells by reducing reactive oxygen species. Am J Hypertens 2002; 15(10 Pt 1): 891-5.</mixed-citation><mixed-citation xml:lang="en">Cominacini L, Pasini A, Garbin U, et al. Zofenopril inhibits the expression of adhesion molecules on endothelial cells by reducing reactive oxygen species. Am J Hypertens 2002; 15(10 Pt 1): 891-5.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Phillips MI, Kimura B. Antisense therapeutics for hypertension: targeting the Renin-Angiotensin system. Methods Mol Med 2004; 106: 51-68.</mixed-citation><mixed-citation xml:lang="en">Phillips MI, Kimura B. Antisense therapeutics for hypertension: targeting the Renin-Angiotensin system. Methods Mol Med 2004; 106: 51-68.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Virdis A, Schiffrin EL. Vascular inflammation: a role in vascular disease in hypertension? Curr Opin Nephrol Hypertens 2003; 12(2): 181-7.</mixed-citation><mixed-citation xml:lang="en">Virdis A, Schiffrin EL. Vascular inflammation: a role in vascular disease in hypertension? Curr Opin Nephrol Hypertens 2003; 12(2): 181-7.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">De Gennaro Colonna V, Rossoni G, Rigamonti A, et al. Enalapril and quinapril improve endothelial vasodilator function and aortic eNOS gene expression in L-NAME-treated rats. Eur J Pharmacol 2002; 450(1): 61-6.</mixed-citation><mixed-citation xml:lang="en">De Gennaro Colonna V, Rossoni G, Rigamonti A, et al. Enalapril and quinapril improve endothelial vasodilator function and aortic eNOS gene expression in L-NAME-treated rats. Eur J Pharmacol 2002; 450(1): 61-6.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Hatta T, Nakata T, Harada S, et al. Lowering of blood pressure improves endothelial dysfunction by increase of NO production in hypertensive rats. Hypert Res 2002; 25(3): 455-60.</mixed-citation><mixed-citation xml:lang="en">Hatta T, Nakata T, Harada S, et al. Lowering of blood pressure improves endothelial dysfunction by increase of NO production in hypertensive rats. Hypert Res 2002; 25(3): 455-60.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Беленков Ю.Н., Мареев В.Ю., Агеев Ф.Г. Эндотелиальная дисфункция при сердечной недостаточности: возможности терапи ингибиторами АПФ. Кардиология 2001; 41(5):100-4.</mixed-citation><mixed-citation xml:lang="en">Беленков Ю.Н., Мареев В.Ю., Агеев Ф.Г. Эндотелиальная дисфункция при сердечной недостаточности: возможности терапи ингибиторами АПФ. Кардиология 2001; 41(5):100-4.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Мордовин В.Ф., Рипп Т.М., Соколов А.А. и др. Динамике показателей эндотелийзависимой вазодилатации и гипотензивная эффективность эналаприла у пациентов с артериальной гипертонией. Кардиология 2001; 41(6): 31-4.</mixed-citation><mixed-citation xml:lang="en">Мордовин В.Ф., Рипп Т.М., Соколов А.А. и др. Динамике показателей эндотелийзависимой вазодилатации и гипотензивная эффективность эналаприла у пациентов с артериальной гипертонией. Кардиология 2001; 41(6): 31-4.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Зотова И.В., Затейщиков Д.А., Сидоренко Б.А. Синтез оксида азота и развитие атеросклероза. Кардиология 2002; 42(4): 58-67.</mixed-citation><mixed-citation xml:lang="en">Зотова И.В., Затейщиков Д.А., Сидоренко Б.А. Синтез оксида азота и развитие атеросклероза. Кардиология 2002; 42(4): 58-67.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Levi-Montalcini R. The nerve growth factor: thirty-five years later. EMBO J 1987; 6: 1145-54.</mixed-citation><mixed-citation xml:lang="en">Levi-Montalcini R. The nerve growth factor: thirty-five years later. EMBO J 1987; 6: 1145-54.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Calza L, Giardino L, Giuliani A, et al. Nerve growth factor control of neuronal expression of angiogenetic and vasoactive factors. Proc Nat Acad Sci USA 2001; 98(7): 4160-5.</mixed-citation><mixed-citation xml:lang="en">Calza L, Giardino L, Giuliani A, et al. Nerve growth factor control of neuronal expression of angiogenetic and vasoactive factors. Proc Nat Acad Sci USA 2001; 98(7): 4160-5.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Гомазков О.А. “Нейротрофические факторы мозга. Справочно-информационное издание”. Электронная версия CD-Rom. Mосква 2004.</mixed-citation><mixed-citation xml:lang="en">Гомазков О.А. “Нейротрофические факторы мозга. Справочно-информационное издание”. Электронная версия CD-Rom. Mосква 2004.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang ZG, Chopp M. VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain. J Clin Invest 2000; 106(7): 829-38.</mixed-citation><mixed-citation xml:lang="en">Zhang ZG, Chopp M. VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain. J Clin Invest 2000; 106(7): 829-38.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Hai J, Li ST, Lin Q, et al. Vascular endothelial growth factor expression and angiogenesis induced by chronic cerebral hypoperfusion in rat brain. Neurosurgery 2003; 53(4): 963-70.</mixed-citation><mixed-citation xml:lang="en">Hai J, Li ST, Lin Q, et al. Vascular endothelial growth factor expression and angiogenesis induced by chronic cerebral hypoperfusion in rat brain. Neurosurgery 2003; 53(4): 963-70.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Zhao Q, Ishibashi M, Hiasa K, et al. Essential Role of vascular endothelial growth factor in angiotensin II-induced vascular inflammation and remodeling. Hypertension 2004; 44(3): 264-70.</mixed-citation><mixed-citation xml:lang="en">Zhao Q, Ishibashi M, Hiasa K, et al. Essential Role of vascular endothelial growth factor in angiotensin II-induced vascular inflammation and remodeling. Hypertension 2004; 44(3): 264-70.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Benndorf R, Boger RH, Ergun S, et al. Angiotensin II type 2 receptor inhibits vascular endothelial growth factor-induced migration and in vitro tube formation of human endothelial cells. Circ Res 2003; 93(5): 438-47.</mixed-citation><mixed-citation xml:lang="en">Benndorf R, Boger RH, Ergun S, et al. Angiotensin II type 2 receptor inhibits vascular endothelial growth factor-induced migration and in vitro tube formation of human endothelial cells. Circ Res 2003; 93(5): 438-47.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Felmeden DC, Spencer CG, Belgore FM, et al. Endothelial damage and angiogenesis in hypertensive patients: relationship to cardiovascular risk factors and risk factor management. Am J Hypertens 2003; 16(1): 11-20.</mixed-citation><mixed-citation xml:lang="en">Felmeden DC, Spencer CG, Belgore FM, et al. Endothelial damage and angiogenesis in hypertensive patients: relationship to cardiovascular risk factors and risk factor management. Am J Hypertens 2003; 16(1): 11-20.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Nadar SK, Blann AD, Lip GY. Plasma and platelet-derived vascular endothelial growth factor and angiopoietin-1 in hypertension: effects of antihypertensive therapy. J Intern Med 2004; 256(4): 331-7.</mixed-citation><mixed-citation xml:lang="en">Nadar SK, Blann AD, Lip GY. Plasma and platelet-derived vascular endothelial growth factor and angiopoietin-1 in hypertension: effects of antihypertensive therapy. J Intern Med 2004; 256(4): 331-7.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Chen J, Wen A, Hong D. [Changes and significance of concentrations of serum vascular endothelial growth factor in patients with pregnancy induced hypertension]. Zhonghua Fu Chan Ke Za Zhi 2000; 35(2): 72-4.</mixed-citation><mixed-citation xml:lang="en">Chen J, Wen A, Hong D. [Changes and significance of concentrations of serum vascular endothelial growth factor in patients with pregnancy induced hypertension]. Zhonghua Fu Chan Ke Za Zhi 2000; 35(2): 72-4.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Nimi H, Arimura K, Jonosono M, et al. VEGF is causative for pulmonary hypertension in patient with Crow-Fukase (POEMS) syndrome. Intern Med 2000; 39(12): 1101-4.</mixed-citation><mixed-citation xml:lang="en">Nimi H, Arimura K, Jonosono M, et al. VEGF is causative for pulmonary hypertension in patient with Crow-Fukase (POEMS) syndrome. Intern Med 2000; 39(12): 1101-4.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Eddahibi S, Humbert M, Sediame S, et al. Imbalance between platelet vascular endothelial growth factor and platelet-derived growth factor in pulmonary hypertension. Effect of prostacyclin therapy. Am J Respir Crit Care Med 2000; 162(4 Pt 1): 1493-9.</mixed-citation><mixed-citation xml:lang="en">Eddahibi S, Humbert M, Sediame S, et al. Imbalance between platelet vascular endothelial growth factor and platelet-derived growth factor in pulmonary hypertension. Effect of prostacyclin therapy. Am J Respir Crit Care Med 2000; 162(4 Pt 1): 1493-9.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Yang R, Ogasawara AK, Zioncheck TF, et al. Exaggerated hypotensive effect of vascular endothelial growth factor in spontaneously hypertensive rats. Hypertension 2002; 39(3): 815-20.</mixed-citation><mixed-citation xml:lang="en">Yang R, Ogasawara AK, Zioncheck TF, et al. Exaggerated hypotensive effect of vascular endothelial growth factor in spontaneously hypertensive rats. Hypertension 2002; 39(3): 815-20.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Quinn TP, Schlueter M, Soifer SJ, Gutierrez JA. Cyclic mechanical stretch induces VEGF and FGF-2 expression in pulmonary vascular smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2002; 282 (5): L897-903.</mixed-citation><mixed-citation xml:lang="en">Quinn TP, Schlueter M, Soifer SJ, Gutierrez JA. Cyclic mechanical stretch induces VEGF and FGF-2 expression in pulmonary vascular smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2002; 282 (5): L897-903.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Partovian C, Adnot S, Eddahibi S, et al. Heart and lung VEGF mRNA expression in rats with monocrotaline- or hypoxia-induced pulmonary hypertension. Am J Physiol 1998; 275(6 Pt 2): H1948-56.</mixed-citation><mixed-citation xml:lang="en">Partovian C, Adnot S, Eddahibi S, et al. Heart and lung VEGF mRNA expression in rats with monocrotaline- or hypoxia-induced pulmonary hypertension. Am J Physiol 1998; 275(6 Pt 2): H1948-56.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Campbell AI, Zhao Y, Sandhu R, Stewart DJ. Cell-based gene transfer of vascular endothelial growth factor attenuates monocrotaline-induced pulmonary hypertension. Circulation 2001; 104(18): 2242-8.</mixed-citation><mixed-citation xml:lang="en">Campbell AI, Zhao Y, Sandhu R, Stewart DJ. Cell-based gene transfer of vascular endothelial growth factor attenuates monocrotaline-induced pulmonary hypertension. Circulation 2001; 104(18): 2242-8.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Li QF, Dai AG. Hypoxia-inducible factor-1 alpha regulates the role of vascular endothelial growth factor on pulmonary arteries of rats with hypoxia-induced pulmonary hypertension. Chin Med J (Engl) 2004; 117(7): 1023-8.</mixed-citation><mixed-citation xml:lang="en">Li QF, Dai AG. Hypoxia-inducible factor-1 alpha regulates the role of vascular endothelial growth factor on pulmonary arteries of rats with hypoxia-induced pulmonary hypertension. Chin Med J (Engl) 2004; 117(7): 1023-8.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Wanstall JC, Gambino A, Jeffery TK, et al. Vascular endothelial growth factor-B-deficient mice show impaired development of hypoxic pulmonary hypertension. Cardiovasc Res 2002; 55(2): 361-8.</mixed-citation><mixed-citation xml:lang="en">Wanstall JC, Gambino A, Jeffery TK, et al. Vascular endothelial growth factor-B-deficient mice show impaired development of hypoxic pulmonary hypertension. Cardiovasc Res 2002; 55(2): 361-8.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Louzier V, Raffestin B, Leroux A, et al. Role of VEGF-B in the lung during development of chronic hypoxic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2003; 284(6): L926-37.</mixed-citation><mixed-citation xml:lang="en">Louzier V, Raffestin B, Leroux A, et al. Role of VEGF-B in the lung during development of chronic hypoxic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2003; 284(6): L926-37.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Taraseviciene-Stewart L, Kasahara Y, Alger L, et al. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J 2001; 15(2): 427-38.</mixed-citation><mixed-citation xml:lang="en">Taraseviciene-Stewart L, Kasahara Y, Alger L, et al. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J 2001; 15(2): 427-38.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Fujita M, Mason RJ, Cool C, et al. Pulmonary hypertension in TNF-alpha-overexpressing mice is associated with decreased VEGF gene expression. J Appl Physiol 2002; 93(6): 2162-70.</mixed-citation><mixed-citation xml:lang="en">Fujita M, Mason RJ, Cool C, et al. Pulmonary hypertension in TNF-alpha-overexpressing mice is associated with decreased VEGF gene expression. J Appl Physiol 2002; 93(6): 2162-70.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Galderisi M, Vitale G, Lupoli G, et al. Inverse association between free insulin-like growth factor-1 and isovolumic relaxation in arterial systemic hypertension. Hypertens 2001; 38(4): 840-5.</mixed-citation><mixed-citation xml:lang="en">Galderisi M, Vitale G, Lupoli G, et al. Inverse association between free insulin-like growth factor-1 and isovolumic relaxation in arterial systemic hypertension. Hypertens 2001; 38(4): 840-5.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Galderisi M, Caso P, Cicala S, et al. Positive association between circulating free insulin-like growth factor-1 levels and coronary flow reserve in arterial systemic hypertension. Am J Hypertens 2002; 15 (9): 766-72.</mixed-citation><mixed-citation xml:lang="en">Galderisi M, Caso P, Cicala S, et al. Positive association between circulating free insulin-like growth factor-1 levels and coronary flow reserve in arterial systemic hypertension. Am J Hypertens 2002; 15 (9): 766-72.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Watanabe T, Itokawa M, Nakagawa Y, et al. Increased levels of insulin-like growth factor binding protein-3 in hypertensive patients with carotid atherosclerosis. Am J Hypertens 2003; 16(9 Pt1): 754-60.</mixed-citation><mixed-citation xml:lang="en">Watanabe T, Itokawa M, Nakagawa Y, et al. Increased levels of insulin-like growth factor binding protein-3 in hypertensive patients with carotid atherosclerosis. Am J Hypertens 2003; 16(9 Pt1): 754-60.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Schut AF, Janssen JA, Deinum J, et al. Polymorphism in the promoter region of the insulin-like growth factor I gene is related to carotid intima-media thickness and aortic pulse wave velocity in subjects with hypertension. Stroke 2003; 34(7): 1623-7.</mixed-citation><mixed-citation xml:lang="en">Schut AF, Janssen JA, Deinum J, et al. Polymorphism in the promoter region of the insulin-like growth factor I gene is related to carotid intima-media thickness and aortic pulse wave velocity in subjects with hypertension. Stroke 2003; 34(7): 1623-7.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Heald AH, Siddals KW, Fraser W, et al. Low circulating levels of insulin-like growth factor binding protein-1 (IGFBP-1) are closely associated with the presence of macrovascular disease and hypertension in type 2 diabetes. Diabetes 2002; 51(8): 2629-36.</mixed-citation><mixed-citation xml:lang="en">Heald AH, Siddals KW, Fraser W, et al. Low circulating levels of insulin-like growth factor binding protein-1 (IGFBP-1) are closely associated with the presence of macrovascular disease and hypertension in type 2 diabetes. Diabetes 2002; 51(8): 2629-36.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Huang CY, Buchanan DL, Gordon RL. Jr, Sherman M.J. et al. Increased insulin-like growth factor-I gene expression precedes left ventricular cardiomyocyte hypertrophy in a rapidlyhypertrophying rat model system. Cell Biochem Funct 2003; 21(4): 355-61.</mixed-citation><mixed-citation xml:lang="en">Huang CY, Buchanan DL, Gordon RL. Jr, Sherman M.J. et al. Increased insulin-like growth factor-I gene expression precedes left ventricular cardiomyocyte hypertrophy in a rapidlyhypertrophying rat model system. Cell Biochem Funct 2003; 21(4): 355-61.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Anwar A, Zahid AA, Phillips L, Delafontaine P. Insulin-like growth factor binding protein-4 expression is decreased by angiotensin II and thrombin in rat aortic vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2000; 20(2): 370-6.</mixed-citation><mixed-citation xml:lang="en">Anwar A, Zahid AA, Phillips L, Delafontaine P. Insulin-like growth factor binding protein-4 expression is decreased by angiotensin II and thrombin in rat aortic vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2000; 20(2): 370-6.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Kamide K, Hori MT, Zhu JH, et al. Insulin and insulin-like growth factor-I promotes angiotensinogen production and growth in vascular smooth muscle cells. J Hypertens 2000; 18(8): 1051-6.</mixed-citation><mixed-citation xml:lang="en">Kamide K, Hori MT, Zhu JH, et al. Insulin and insulin-like growth factor-I promotes angiotensinogen production and growth in vascular smooth muscle cells. J Hypertens 2000; 18(8): 1051-6.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Muller C, Reddert A, Wassmann S, et al. Insulin-like growth factor induces up-regulation of AT(1)-receptor gene expression in vascular smooth muscle cells. J Renin Angiotensin Aldosterone Syst 2000; 1(3): 273-7.</mixed-citation><mixed-citation xml:lang="en">Muller C, Reddert A, Wassmann S, et al. Insulin-like growth factor induces up-regulation of AT(1)-receptor gene expression in vascular smooth muscle cells. J Renin Angiotensin Aldosterone Syst 2000; 1(3): 273-7.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Nishishita T, Lin PC. Angiopoietin 1, PDGF-B, and TGF-beta gene regulation in endothelial cell and smooth muscle cell interaction. J Cell Biochem 2004; 91(3): 584-93.</mixed-citation><mixed-citation xml:lang="en">Nishishita T, Lin PC. Angiopoietin 1, PDGF-B, and TGF-beta gene regulation in endothelial cell and smooth muscle cell interaction. J Cell Biochem 2004; 91(3): 584-93.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Englesbe MJ, Hawkins SM, Hsieh PC, et al. Concomitant blockade of platelet-derived growth factor receptors alpha and beta induces intimal atrophy in baboon PTFE grafts. J Vasc Surg 2004; 39(2): 440-6.</mixed-citation><mixed-citation xml:lang="en">Englesbe MJ, Hawkins SM, Hsieh PC, et al. Concomitant blockade of platelet-derived growth factor receptors alpha and beta induces intimal atrophy in baboon PTFE grafts. J Vasc Surg 2004; 39(2): 440-6.</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Sack FU, Vielfort TJ, Koch A, et al. The role of platelet derived growth factor in endomyocardial biopsies shortly after heart transplantation in relation to postoperative course. Eur J Cardiothorac Surg 2004; 25(1): 91-7.</mixed-citation><mixed-citation xml:lang="en">Sack FU, Vielfort TJ, Koch A, et al. The role of platelet derived growth factor in endomyocardial biopsies shortly after heart transplantation in relation to postoperative course. Eur J Cardiothorac Surg 2004; 25(1): 91-7.</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Tanabe Y, Saito M, Ueno A, et al. Mechanical stretch augments PDGF receptor beta expression and protein tyrosine phosphorylation in pulmonary artery tissue and smooth muscle cells. Mol Cell Biochem 2000; 215(1-2): 103-13.</mixed-citation><mixed-citation xml:lang="en">Tanabe Y, Saito M, Ueno A, et al. Mechanical stretch augments PDGF receptor beta expression and protein tyrosine phosphorylation in pulmonary artery tissue and smooth muscle cells. Mol Cell Biochem 2000; 215(1-2): 103-13.</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Kim S, Zhan Y, Izumi Y, et al. In vivo activation of rat aortic platelet-derived growth factor and epidermal growth factor receptors by angiotensin II and hypertension. Arterioscler Thromb Vasc Biol 2000; 20(12): 2539-45.</mixed-citation><mixed-citation xml:lang="en">Kim S, Zhan Y, Izumi Y, et al. In vivo activation of rat aortic platelet-derived growth factor and epidermal growth factor receptors by angiotensin II and hypertension. Arterioscler Thromb Vasc Biol 2000; 20(12): 2539-45.</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Kishioka H, Fukuda N, Wen-Yang H, et al. Effects of PDGF Achain antisense oligodeoxynucleotides on growth of cardiovascular organs in stroke-prone spontaneously hypertensive rats. Am J Hypertens 2001; 14(5 Pt 1): 439-45.</mixed-citation><mixed-citation xml:lang="en">Kishioka H, Fukuda N, Wen-Yang H, et al. Effects of PDGF Achain antisense oligodeoxynucleotides on growth of cardiovascular organs in stroke-prone spontaneously hypertensive rats. Am J Hypertens 2001; 14(5 Pt 1): 439-45.</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Miller-Kasprzak E, Niemir ZI, Czekalski S. The role of platelet-derived growth factor A (PDGF-A) in hypertension and renal diseases. Part 2: a role of PDGF-A in kidney diseases. Pol Merkuriusz Lek 2004; 16(94): 403-5.</mixed-citation><mixed-citation xml:lang="en">Miller-Kasprzak E, Niemir ZI, Czekalski S. The role of platelet-derived growth factor A (PDGF-A) in hypertension and renal diseases. Part 2: a role of PDGF-A in kidney diseases. Pol Merkuriusz Lek 2004; 16(94): 403-5.</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Intiso D, Zarrelli MM, Lagioia G, et al. Tumor necrosis factor alpha serum levels and inflammatory response in acute ischemic stroke patients. Neurol Sci 2004; 24(6): 390-6.</mixed-citation><mixed-citation xml:lang="en">Intiso D, Zarrelli MM, Lagioia G, et al. Tumor necrosis factor alpha serum levels and inflammatory response in acute ischemic stroke patients. Neurol Sci 2004; 24(6): 390-6.</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Kadokami T. Antitumor necrosis factor-alpha antibody limits heart failure in a transgenic model. Circulation 2001; 104(10): 1094-7.</mixed-citation><mixed-citation xml:lang="en">Kadokami T. Antitumor necrosis factor-alpha antibody limits heart failure in a transgenic model. Circulation 2001; 104(10): 1094-7.</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Sheu WHH, Lee WJ, Chang RL, Chen YT. Plasma tumor necrosis factor alpha levels and insulin sensitivity in hypertensive subjects. Clin Exper Hypert 2000; 22(6): 595-606.</mixed-citation><mixed-citation xml:lang="en">Sheu WHH, Lee WJ, Chang RL, Chen YT. Plasma tumor necrosis factor alpha levels and insulin sensitivity in hypertensive subjects. Clin Exper Hypert 2000; 22(6): 595-606.</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Bautista LE, Vera LM, Arenas IA, Gamarra G. Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension. J Hum Hypertens 2005; 19(2): 149-54.</mixed-citation><mixed-citation xml:lang="en">Bautista LE, Vera LM, Arenas IA, Gamarra G. Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension. J Hum Hypertens 2005; 19(2): 149-54.</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Goumans MJ, Lebrin F, Valdimarsdottir G. Controlling the angiogenic switch: a balance between two distinct TGF-b receptor signaling pathways. Trends Cardiovasc Med 2003; 13(7): 301-7.</mixed-citation><mixed-citation xml:lang="en">Goumans MJ, Lebrin F, Valdimarsdottir G. Controlling the angiogenic switch: a balance between two distinct TGF-b receptor signaling pathways. Trends Cardiovasc Med 2003; 13(7): 301-7.</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Lijnen PJ, Petrov VV, Fagard RH. Association between transforming growth factor-beta and hypertension. Am J Hypertens 2003; 16(7): 604-11.</mixed-citation><mixed-citation xml:lang="en">Lijnen PJ, Petrov VV, Fagard RH. Association between transforming growth factor-beta and hypertension. Am J Hypertens 2003; 16(7): 604-11.</mixed-citation></citation-alternatives></ref><ref id="cit61"><label>61</label><citation-alternatives><mixed-citation xml:lang="ru">Le Cras TD, Hardie WD, Fagan K, et al. Disrupted pulmonary vascular development and pulmonary hypertension in transgenic mice overexpressing transforming growth factor-alpha. Am J Physiol Lung Cell Mol Physiol 2003; 285(5): L1046-54.</mixed-citation><mixed-citation xml:lang="en">Le Cras TD, Hardie WD, Fagan K, et al. Disrupted pulmonary vascular development and pulmonary hypertension in transgenic mice overexpressing transforming growth factor-alpha. Am J Physiol Lung Cell Mol Physiol 2003; 285(5): L1046-54.</mixed-citation></citation-alternatives></ref><ref id="cit62"><label>62</label><citation-alternatives><mixed-citation xml:lang="ru">Ying WZ, Sanders PW. The interrelationship between TGF-beta1 and nitric oxide is altered in salt-sensitive hypertension. Am J Physiol Renal Physiol 2003; 285(5): F902-8.</mixed-citation><mixed-citation xml:lang="en">Ying WZ, Sanders PW. The interrelationship between TGF-beta1 and nitric oxide is altered in salt-sensitive hypertension. Am J Physiol Renal Physiol 2003; 285(5): F902-8.</mixed-citation></citation-alternatives></ref><ref id="cit63"><label>63</label><citation-alternatives><mixed-citation xml:lang="ru">Tahira Y, Fukuda N, Endo M, et al. Transforming growth factorbeta expression in cardiovascular organs in stroke-prone spontaneously hypertensive rats with the development of hypertension. Hypertens Res 2002; 25(6): 911-8.</mixed-citation><mixed-citation xml:lang="en">Tahira Y, Fukuda N, Endo M, et al. Transforming growth factorbeta expression in cardiovascular organs in stroke-prone spontaneously hypertensive rats with the development of hypertension. Hypertens Res 2002; 25(6): 911-8.</mixed-citation></citation-alternatives></ref><ref id="cit64"><label>64</label><citation-alternatives><mixed-citation xml:lang="ru">Srivastava S, Terjung RL, Yang HT. Basic fibroblast growth factor increases collateral blood flow in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 2003; 285(3): H1190-7.</mixed-citation><mixed-citation xml:lang="en">Srivastava S, Terjung RL, Yang HT. Basic fibroblast growth factor increases collateral blood flow in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 2003; 285(3): H1190-7.</mixed-citation></citation-alternatives></ref><ref id="cit65"><label>65</label><citation-alternatives><mixed-citation xml:lang="ru">Benisty JI, McLaughlin VV, Landzberg MJ, et al. Elevated basic fibroblast growth factor levels in patients with pulmonary arterial hypertension. Chest 2004; 126(4): 1255-61.</mixed-citation><mixed-citation xml:lang="en">Benisty JI, McLaughlin VV, Landzberg MJ, et al. Elevated basic fibroblast growth factor levels in patients with pulmonary arterial hypertension. Chest 2004; 126(4): 1255-61.</mixed-citation></citation-alternatives></ref><ref id="cit66"><label>66</label><citation-alternatives><mixed-citation xml:lang="ru">Hohlagschwandtner M, Knofler M, Ploner M, et al. Basic fibroblast growth factor and hypertensive disorders in pregnancy. Hypertens Pregnancy 2002; 21(3): 235-41.</mixed-citation><mixed-citation xml:lang="en">Hohlagschwandtner M, Knofler M, Ploner M, et al. Basic fibroblast growth factor and hypertensive disorders in pregnancy. Hypertens Pregnancy 2002; 21(3): 235-41.</mixed-citation></citation-alternatives></ref><ref id="cit67"><label>67</label><citation-alternatives><mixed-citation xml:lang="ru">Biswas SS, Hughes GC, Scarborough JE, et al. Intramyocardial and intracoronary basic fibroblast growth factor in porcine hibernating myocardium: A comparative study. J Thorac Cardiovasc Surg 2004; 127(1): 34-43.</mixed-citation><mixed-citation xml:lang="en">Biswas SS, Hughes GC, Scarborough JE, et al. Intramyocardial and intracoronary basic fibroblast growth factor in porcine hibernating myocardium: A comparative study. J Thorac Cardiovasc Surg 2004; 127(1): 34-43.</mixed-citation></citation-alternatives></ref><ref id="cit68"><label>68</label><citation-alternatives><mixed-citation xml:lang="ru">68. Fu P, Sodian R, Luders C, et al. Effects of basic fibroblast growth factor and transforming growth factor-beta on maturation of human pediatric aortic cell culture for tissue engineering of cardiovascular structures. ASAIO J 2004; 50(1): 9-14.</mixed-citation><mixed-citation xml:lang="en">68. Fu P, Sodian R, Luders C, et al. Effects of basic fibroblast growth factor and transforming growth factor-beta on maturation of human pediatric aortic cell culture for tissue engineering of cardiovascular structures. ASAIO J 2004; 50(1): 9-14.</mixed-citation></citation-alternatives></ref><ref id="cit69"><label>69</label><citation-alternatives><mixed-citation xml:lang="ru">Kanda S, Miyata Y., Kanetake H. Fibroblast growth factor-2- mediated capillary morphogenesis of endothelial cells requires signals via Flt-1/vascular endothelial growth factor receptor-1: possible involvement of c-Akt. J Biol Chem 2004; 279(6): 4007- 16.</mixed-citation><mixed-citation xml:lang="en">Kanda S, Miyata Y., Kanetake H. Fibroblast growth factor-2- mediated capillary morphogenesis of endothelial cells requires signals via Flt-1/vascular endothelial growth factor receptor-1: possible involvement of c-Akt. J Biol Chem 2004; 279(6): 4007- 16.</mixed-citation></citation-alternatives></ref><ref id="cit70"><label>70</label><citation-alternatives><mixed-citation xml:lang="ru">Mombouli JV, Vanhoutte PM. Endothelial dysfunction: From physiology to therapy. J Mol Cell Cardiol 1999; 31(1): 61-74.</mixed-citation><mixed-citation xml:lang="en">Mombouli JV, Vanhoutte PM. Endothelial dysfunction: From physiology to therapy. J Mol Cell Cardiol 1999; 31(1): 61-74.</mixed-citation></citation-alternatives></ref><ref id="cit71"><label>71</label><citation-alternatives><mixed-citation xml:lang="ru">Pahor M, Elam MB, Garrison RJ, et al. Emerging noninvasive biochemical measures to predict cardiovascular risk. Arch Intern Med 1999; 159(3): 237-45.</mixed-citation><mixed-citation xml:lang="en">Pahor M, Elam MB, Garrison RJ, et al. Emerging noninvasive biochemical measures to predict cardiovascular risk. Arch Intern Med 1999; 159(3): 237-45.</mixed-citation></citation-alternatives></ref><ref id="cit72"><label>72</label><citation-alternatives><mixed-citation xml:lang="ru">Sautiere K, Susen F, Cuillereta G. Hepatocyte Growth Factor and VEGF serum level: risk factors for clinical events at one year after PTCA. Europ Soc Cardiol Congres (Munich) 2004; poster 1343.</mixed-citation><mixed-citation xml:lang="en">Sautiere K, Susen F, Cuillereta G. Hepatocyte Growth Factor and VEGF serum level: risk factors for clinical events at one year after PTCA. Europ Soc Cardiol Congres (Munich) 2004; poster 1343.</mixed-citation></citation-alternatives></ref><ref id="cit73"><label>73</label><citation-alternatives><mixed-citation xml:lang="ru">Iacobellis G, Cipriani R, Gabriele A, et al. High circulating vascular endothelial growth factor (VEGF) is related to a better systolic function in diabetic hypertensive patients. Cytokine 2004; 27(1): 25-30.</mixed-citation><mixed-citation xml:lang="en">Iacobellis G, Cipriani R, Gabriele A, et al. High circulating vascular endothelial growth factor (VEGF) is related to a better systolic function in diabetic hypertensive patients. Cytokine 2004; 27(1): 25-30.</mixed-citation></citation-alternatives></ref><ref id="cit74"><label>74</label><citation-alternatives><mixed-citation xml:lang="ru">Witthaut W, Stövesandt X, Prondzinsky A, et al. Elevated TNF-alpha in acute myocardial infarction following primary angioplasty is associated with poor prognosis. J Hypert 2003; 21(Suppl 4): 913.</mixed-citation><mixed-citation xml:lang="en">Witthaut W, Stövesandt X, Prondzinsky A, et al. Elevated TNF-alpha in acute myocardial infarction following primary angioplasty is associated with poor prognosis. J Hypert 2003; 21(Suppl 4): 913.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
